Albany, NY -- (SBWIRE) -- 12/09/2019 -- Neuromyelitis Optica Spectrum Disorder Market Insights, Epidemiology and Market Forecast-2028

(Albany, US) DelveInsight launched a new report on Neuromyelitis Optica Spectrum Disorder Market Insights, Epidemiology and Market Forecast-2028

Some of the key facts of the report

1. The total Neuromyelitis Optica Spectrum Disorder prevalent population in the 7 major was 32,382 cases in 2016.
2. A total of 13,212 monophasic and 6,217 recurrent event cases of Neuromyelitis Optica Spectrum Disorder were diagnosed in 2016 in 7MM.

Key benefits of the report

1. Neuromyelitis Optica Spectrum Disorder market report covers a descriptive overview and comprehensive insight of the Neuromyelitis Optica Spectrum Disorder epidemiology and Neuromyelitis Optica Spectrum Disorder market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Neuromyelitis Optica Spectrum Disorder market report provides insights on the current and emerging therapies.
3. Neuromyelitis Optica Spectrum Disorder market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Neuromyelitis Optica Spectrum Disorder market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Neuromyelitis Optica Spectrum Disorder market.

Request for sample pages

"Neuromyelitis Optica Spectrum Disorder affects approximately 0.4 per 10,000 population in Europe, which is equivalent to approximately 2,564 people in the United Kingdom."

Neuromyelitis Optica market size in the seven major markets was USD 145.1 million in 2016. The United States accounts for the largest Neuromyelitis Optica Spectrum Disorder market size in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. The United States accounted for 53.1 % of the total sales in 2016.

Currently, there is no cure for Neuromyelitis Optica and the existing treatment regimen is focused completely towards the improvement of acute symptoms and prevention of frequent recurrences. The current therapeutic Neuromyelitis Optica Spectrum Disorder market is dependent on the use of Methylprednisolone, Mitoxantrone/Cyclophosphamide, IVIG, Prednisolone, Azathioprine, Rituximab, Mycophenolate Mofetil, Ciclosporin/Tacrolimus, and Methotrexate. Even though various off-label therapeutic approaches are available, still Neuromyelitis Optica Spectrum Disorder is often characterized by relapses that require hospitalization, extensive outpatient care, and/or treatment. Also, the low availability of plasma, unproven efficacy of off-label drugs, intolerable side effects of immunosuppressants, unknown mechanism of corticosteroids, and the high cost of therapy in case of refractory and relapsed patients have emerged the need of better therapy for Neuromyelitis Optica Spectrum Disorder treatment. As the diagnosed prevalence of the disease is increasing along with the promising emerging pipeline therapies are coming up, will fuel Neuromyelitis Optica Spectrum Disorder market during the forecasted period of 2018-2027.

The launch of the emerging therapies is expected to significantly impact Neuromyelitis Optica Spectrum Disorder treatment scenario in the upcoming years:-
Drugs covered
1. Satralizumab
2. Soliris
3. MEDI-551
And many others

The key players in Neuromyelitis Optica Spectrum Disorder market are:
1. Alexion Pharma
2. Chugai Pharmaceutical
3. Roche
4. Viela Bio
And many others

Table of contents

1. Key Insights
2. Neuromyelitis Optica Spectrum Disorder Market Overview at a Glance
3. Neuromyelitis Optica Spectrum Disorder Disease Background and Overview
4. Neuromyelitis Optica Spectrum Disorder Epidemiology and Patient Population
5. 7MM Total Prevalent Patient Population of Neuromyelitis Optica Spectrum Disorder
6. Country Wise Neuromyelitis Optica Spectrum Disorder Epidemiology
6.1. United States
6.2. EU5 Countries
6.3. Germany
6.4. France
6.5. Italy
6.6. United Kingdom
6.7. Spain
6.8. Japan
7. Neuromyelitis Optica Spectrum Disorder Treatment
8. Unmet Needs
9. Key Cross Competitors
10. Neuromyelitis Optica Spectrum Disorder Emerging Drugs
10.1. MEDI-551: Viela Bio
10.2. Satralizumab (SA237): Chugai Pharmaceutical/ Roche
10.3. Soliris: Alexion Pharma
11. Neuromyelitis Optica 7 Major Market Analysis
12. United States Market Outlook
12.1. United States Market Size
13. EU-5 Countries: Market Outlook
13.1. Germany
13.2. France
13.3. Italy
13.4. United Kingdom
13.5. Spain
14. Japan: Market Outlook
15. Market Drivers
16. Market Barriers
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight